NCT04962269

Completed

Application of DWI in Diagnosis of Prostate Cancer

Peking University Third Hospital Source

Compare

Other study identifiers

Sponsor study identifier

M2019176

Study Type

observational

Actual enrollment (reported)

103

Locations

0 countries

Sites

N/A

Timeline

Study Start

June 12, 2013

Actual (reported)

Primary Completion

June 21, 2018

Actual (reported)

Study Completion

June 21, 2018

Actual (reported)

Brief Summary

This study compared the performance of different models of multiple b-value DWI in diagnosing prostate cancer.

Registry Overview

Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.

Recruitment status: completed
Actual enrollment (reported): 103 participants
Study completion date: June 21, 2018
Actual (reported)
Listed locations: 0 countries · 0 sites

Trial Relationships

Click on a node to explore related trials.

Some registry-reported names shown below are not yet linked in this graph.

Study Timeline

Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.

Study Start
June 12, 2013
Actual (reported)
Primary Completion
June 21, 2018
Actual (reported)
Study Completion
June 21, 2018
Actual (reported)
First Submitted
June 29, 2021
Actual (reported)
First Posted
July 14, 2021
Actual (reported)

Last Updated: July 14, 2021
Status Verified: June 2021
Last Update Submitted: July 4, 2021

Conditions

Benign Prostatic Hyperplasia Prostate Cancer

Keywords

benign prostatic hyperplasiaDiffusion weighted imaging

Outcome Measures

Primary Outcomes (1)

pathological diagnosis
prostate cancer or benign prostatic hyperplasia
2013.10-2018.6

Study Arms (2)

prostate cancer

The patient was pathologically diagnosed with prostate cancer

Diagnostic Test: MRI

benign prostatic hyperplasia

The patient was pathologically diagnosed with benign prostatic hyperplasia

Interventions

MRIDiagnostic test

monoexponential model, intravoxel incoherent motion (IVIM) model and stretched exponential model

prostate cancer

Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.

Eligibility Criteria

Sexmale

Healthy VolunteersNo

Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)

Sampling MethodNon-Probability Sample

Study Population

patients with prostatic diseases confirmed as prostate cancer or benign prostatic hyperplasia

You may qualify if:

The exam including T1WI、T2WI and multiple b-value DWI.

Sponsors & Collaborators

Peking University Third Hospital
Otherlead

MeSH Terms

Conditions

Prostatic NeoplasmsProstatic Hyperplasia

Condition Hierarchy (Ancestors)

Genital Neoplasms, MaleUrogenital NeoplasmsNeoplasms by SiteNeoplasmsGenital Diseases, MaleGenital DiseasesUrogenital DiseasesProstatic DiseasesMale Urogenital Diseases

Study Officials

Jianyu Liu
Peking University
STUDY DIRECTOR

Enrollment

103 participants (actual enrollment reported by the registry).

Study Design

Study Type: observational
Observational Model: CASE CONTROL
Time Perspective: RETROSPECTIVE
Sponsor Type: OTHER
Responsible Party: SPONSOR

Study Record Dates

First Submitted

June 29, 2021

First Posted

July 14, 2021

Study Start

June 12, 2013

Actual (reported)

NCT06607783

PRostate Cancer Enhanced Diagnosis by Calibration Technology

Recruiting

NCT00242060

Functional and Morphologic MRI in the Detection of Prostate Cancer in Patients With Prior Negative Biopsy

Not ApplicableCompleted

NCT01314456

3D Recording of a Trans-rectal Prostate Biopsy

Not ApplicableUnknown

NCT01959542

Early Changes In Multiparametric MRI In Prostate Cancer

Not ApplicableCompleted

NCT01177436

Prostate Cancer Antigen 3 (PCA-3) Gene Project

Not ApplicableCompleted

NCT03817216

Prostatic Urethral Lift (PUL) Pre-/Post-Radiation Treatment for Prostate Cancer

Not ApplicableWithdrawn

Comfired by pathology as prostate cancer or benign prostatic hyperplasia in one month after the MRI exam.

You may not qualify if:

No Gleason score data. 2.Awful quality of imagings or artifacts affectting diagnosis. 3.No lesion larger than 0.5cm. 4.Any surgery or treatment before MRI exam. 5.Biopsy in 4 weeks before MRI exam.

Contact the study team to confirm eligibility.

Primary Completion

June 21, 2018

Actual (reported)

Study Completion

June 21, 2018

Actual (reported)

Last Updated

July 14, 2021

Record last verified: 2021-06

Data Sharing

IPD Sharing: Will not share

Source record

Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.

Source: ClinicalTrials.gov.

JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.

Registry identifier: NCT04962269
Data provider: ClinicalTrials.gov
Source updated: 2021-07-14
Normalization version: ctgov-legacy-1

Open registry record

Source retrieved: 2026-10-25 22:27:19 UTC

Brief Summary

Registry Overview

Trial Relationships

Related Scientific Literature

Study Timeline

Study Start

Primary Completion

Study Completion

First Submitted

First Posted

Conditions

Keywords

Outcome Measures

Primary Outcomes (1)

Study Arms (2)

prostate cancer

benign prostatic hyperplasia

Interventions

Eligibility Criteria

You may qualify if:

Sponsors & Collaborators

MeSH Terms

Conditions

Condition Hierarchy (Ancestors)

Study Officials

Enrollment

Study Design

Study Record Dates

You may not qualify if:

Data Sharing

Source record